RBI’s President and Founder Presents Breakthrough Stem Cell Therapy For CNS Disorders.
At the 2024 ISCT Annual Meeting, Dr. Christopher Duma of Regeneration Biomedical, Inc. (RBI) presented encouraging early data from a first-in-human trial of its CEREWiNT™ stem cell platform for Alzheimer’s and related diseases. The therapy delivers Wnt-activated autologous stem cells directly into the brain, aiming to regenerate rather than just manage symptoms. Preliminary results show […]
PFD Announces Regeneration Biomedical As A Portfolio Company In Upcoming Hybrid Medical Receivables Fund
Announced today by Robert Pryke, PFD Capital Partners LLC, Director and Fund Manager for PFD Special Medical Receivables Hybrid (SMH) 3002, that Regeneration Biomedical, Inc. (RBI)—a clinical-stage biotechnology company advancing stem cell-based therapies for neurodegenerative diseases—will be included in its upcoming PFDSMH3002.
PFDSelect Medical Receivables 1013, LLC Has Officially Closed To New Investors
Gary L. Ermoian, COO & Co-founder, today announced PFDSelect Medical Receivables 1013, LLC has officially closed to new investors. The manager informed the capital team that the offering reached its maximum investor allocation as of Tuesday, May 20, 2025.